Federated Hermes’s Ovid Therapeutics OVID Stock Holding History

Federated Hermes’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16M	Buy	5,951,666 +2,380,666	+67%	+$6.14M	0.02%	554
2026 Q1	$7.93M	Hold	3,571,000	–	–	0.01%	701
2025 Q4	$5.31M	Buy	+3,571,000	New	+$5.5M	0.01%	773
2024 Q3	–	Sell	-2,250	Closed	-$1.73K	–	2135
2024 Q2	$1.73K	Buy	+2,250	New	+$6.26K	﹤0.01%	1909
2022 Q1	–	Sell	-1,887	Closed	-$6K	–	2277
2021 Q4	$6K	Buy	1,887 +656	+53%	+$2.25K	﹤0.01%	1980
2021 Q3	$4K	Buy	1,231 +981	+392%	+$3.58K	﹤0.01%	2057
2021 Q2	$1K	Buy	+250	New	+$987	﹤0.01%	2148
2021 Q1	–	Sell	-483	Closed	-$1K	–	2323
2020 Q4	$1K	Sell	483 -1,775	-79%	-$8.27K	﹤0.01%	2187
2020 Q3	$13K	Buy	2,258 +2,037	+922%	+$13.6K	﹤0.01%	1940
2020 Q2	$2K	Sell	221 -1	-0.5%	-$5	﹤0.01%	2087
2020 Q1	$1K	Sell	222 -98	-31%	-$330	﹤0.01%	2140
2019 Q4	$1K	Buy	+320	New	+$1.01K	﹤0.01%	2126

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Federated Hermes's OVID Position: Q2 2026 in Review

Federated Hermes increased its Ovid Therapeutics (OVID) stake by 67% in Q2 2026, buying an estimated $6.14M and bringing the position to 5,951,666 shares worth $16M. The position accounts for 0.02% of the portfolio, ranked #554.

Federated Hermes first reported a position in OVID in Q4 2019 and has held it in 12 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Federated Hermes held 5,951,666 shares of Ovid Therapeutics worth $16M as of Q2 2026.
Federated Hermes bought 2,380,666 Ovid Therapeutics shares in Q2 2026, an estimated $6.14M.
Ovid Therapeutics made up 0.02% of Federated Hermes's portfolio in Q2 2026, its #554 holding.
Federated Hermes first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 12 quarters since.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.